Fangzhou Valuation
Is 6086 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6086 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6086 (HK$5.94) is trading above our estimate of fair value (HK$3.16)
Significantly Below Fair Value: 6086 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6086?
Key metric: As 6086 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6086's PS Ratio? | |
|---|---|
| PS Ratio | 3x |
| Sales | CN¥2.47b |
| Market Cap | CN¥7.40b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | -12.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6086's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
314 Sipai Health Technology | 0.9x | 16.6% | HK$4.5b |
1833 Ping An Healthcare and Technology | 3.3x | 7.0% | HK$16.0b |
241 Alibaba Health Information Technology | 1.9x | 9.7% | HK$57.9b |
9886 Dingdang Health Technology Group | 0.1x | 13.1% | HK$754.1m |
6086 Fangzhou | 3x | n/a | HK$8.0b |
Price-To-Sales vs Peers: 6086 is expensive based on its Price-To-Sales Ratio (3x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does 6086's PS Ratio compare vs other companies in the HK Consumer Retailing Industry?
Price-To-Sales vs Industry: 6086 is expensive based on its Price-To-Sales Ratio (3x) compared to the Hong Kong Consumer Retailing industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 6086's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6086's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.